Current Clinical Trials in South Florida

Current Clinical Trials

Healthcare is constantly evolving, and at Broward Health, we’re committed to improving the care we provide. For generations, we have delivered comprehensive care that makes a difference. Our specialty services and diverse patient population drive lifesaving pharmaceutical research and clinical trials, creating a healthier future for all.

Broward Health offers a range of clinical trials, giving patients access to innovative treatments while advancing medical knowledge. See below for a list of currently enrolling trials. Please note: availability may change, and not all patients may qualify. Speak with your provider to see if one of our clinical trials is right for you.

ADULT CANCER RESEARCH

Breast
Alliance A012103: OptimICE-PCR: Deescalation of Therapy in Early Stage TNBC Patients who Achieve pCR after Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
Alliance A212102: Blinded Reference Set for Multicancer Early Detection Blood Tests
NRG-CC011: Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors: A Multi-Center Randomized Double-Blinded Controlled Trial
SWOG S2212: Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study
Latimer breast cancer fresh tissue and blood study (Biomarker)
Retrospective analyses of genetic testing performed in patients with breast, ovarian and endometrial cancer
Endometrial
NRG-GY-026: Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma Open to accrual: Upfront treatment for stage I-IV uterine serous carcinoma or carcinosarcoma
GOG-3105: A Phase III, Randomized, Multi-site, Open-Label Trial of BNT323/DB1303 versus Investigator's Choice of Chemotherapy in Previously Treated Patients with HER2-expressing Recurrent Endometrial Cancer
GOG-3122: A Phase 3, Multicenter, Randomized, Open-Label Trial of Trastuzumab Deruxtecan versus Standard of Care Chemotherapy With or Without Radiotherapy as Adjuvant Treatment for HER2-Expressing (IHC 3+/2+) Endometrial Cancer / (DESTINY-Endometrial02/GOG3122/ENGOT-en30/GINECO)

Uterine
GOG-3088: A Randomized Phase II Study of Letrozole versus Observation in Patients with Newly Diagnosed Uterine Leiomyasarcoma

Ovarian
NRG-GY036: A Phase III Trial of One vs. Two Years of Maintenance Olaparib, with or without Bevacizumab, in Patients with BRCA 1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum-Based Chemotherapy
GOG-3133: FRAMEWORK-01: A Two-Part Phase 3 Study of LY4170156 versus Chemotherapy or Mirvetuxumab Soravtansine in Platinum-Resistant Ovarian Cancer, and LY4170156 plus Bevacizumab versus Platinum-Based Chemotherapy plus Bevacizumab in Platinum-Sensitive Ovarian Cancer
Biospecimen
Utility of molecular diagnostics from cervicovaginal sampling in endometrial cancer
SERATRIALS-18004: A Multi-Center Study for the Collection of Biospecimens for Research; Surplus Surgical Tissues and Surplus/Non-Surplus Biofluids for In-Vitro Research
MTG-022: Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized Management of Patients
AOA-PR-0001: Collection and Banking of Blood Samples for the Study of Female Gynecological Diseases
Caris Biorepository Research: Study A - Newly Diagnosed Pan-Cancer Cohort Study; Study B - Pre-Biopsy Breast Collection Cohort
Other
EAY191: Molecular Analysis for Combination Therapy Choice (Combo Match)
NRG-GY037: A Phase III Study of Induction Pembrolizumab and Chemotherapy Followed by Chemoradiation and Pembrolizumab vs Chemoradiation and Pembrolizumab both Followed by Pembrolizumab for High Risk Locally Advanced Cervical Cancer
GOG-3112: A Phase 3, Open-label, Multicenter, Randomized Trial of Trastuzumab Deruxtecan with Bevacizumab Vs. Bevacizumab Monotherapy as First-Line Therapy in HER2-Expressing Ovarian Cancer (DESTINY)
Moonshot: National Cancer Institute / Cancer Moonshot Biobank Research Protocol
GOG3116: A Propsective Low-Interventional Phase 4 Single Arm Study of Ocular Assessments in Patients Treated with TIVDAK in Recurrent or Metastatic Cervical Cancer

CARDIOVASCULAR RESEARCH

Dal-GenE-2: A Phase III, Double-Blind, Randomized Placebo-Controlled Study to Evaluate the Effecs of Dalcetrapib on Cardiovascular (CV) Risk in Genetically Defined Population with a Recent Acute Coronary Syndrome (ACS): The DAL-302 (dal-GenE-2) Trial
REDEFINE: Randomized Trial to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality among Heart Failure Patients with Left Ventricular Ejection Fraction Greater than or Equal to 40% Hospitalized Due to an Episode of Acute Decompensated Heart Failure
CONFIRMATION: Combined Efficacy and Safety of an Early, Intensive Management Strategy with Finerenone and SGLT2 iNhibitor in Patients Hospitalized with Heart Failure
EMPOWER: Assessment of the Carillon Mitral Contour System in Treating Heart Failure with Functional Mitral Regurgitation
DRAIN-HF: Diuretics Alone vs Aortix Endovascular Device for Acute Heart Failure

NEUROLOGY

ASPIRE: Anticoagulation in Intracerebral Hemorrhage (ICH) Survivors for Stroke Prevention and Recovery
CAR: Complex Aneurysm Registry - Real-World Evidence Data Collection for Intracranial Aneurysm Treatment Devices
BT012: A Randomized Pivotal Study Assessing the Safety and Efficacy of Targeted Blood-Brain Barrier (BBB) Opening Using Exablate Focused Ultrasound During the Standard of Care Treatment of Brain Metastases of Non-Small Cell Lung Cancer (NSCLC) Origin
AL002: Assessment of Safety and Efficacy of Exablate Blood-Brain Barrier Disruption for the Treatment of Patients with Probable Alzheimer's Disease
ADAPT 2.0: Clinical Evaluation of Continuous Dual Aspiration Technique with Zoom System for Stroke